Jeffrey W. Albers - Dec 19, 2024 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
Director
Signature
/s/ Melissa Masse, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
Dec 19, 2024
Transactions value $
-$1,346,615
Form type
4
Date filed
12/20/2024, 04:15 PM
Previous filing
Nov 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $541K +15K +9.52% $36.05 173K Dec 19, 2024 Direct F1
transaction BPMC Common Stock Sale -$346K -3.92K -2.27% $88.28 169K Dec 19, 2024 Direct F1, F2
transaction BPMC Common Stock Sale -$461K -5.18K -3.07% $89.01 163K Dec 19, 2024 Direct F1, F3
transaction BPMC Common Stock Sale -$346K -3.8K -2.32% $91.15 160K Dec 19, 2024 Direct F1, F4
transaction BPMC Common Stock Sale -$193K -2.1K -1.32% $91.96 158K Dec 19, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise -$541K -15K -11.11% $36.05 120K Dec 19, 2024 Common Stock 15K $36.05 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $87.60 to $88.49 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $88.63 to $89.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.79 to $91.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $91.84 to $92.15 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 This option was granted on February 16, 2017 and is fully vested as of the transaction date.